CN116270567A - Pharmaceutical preparation for treating diabetes - Google Patents
Pharmaceutical preparation for treating diabetes Download PDFInfo
- Publication number
- CN116270567A CN116270567A CN202310242383.2A CN202310242383A CN116270567A CN 116270567 A CN116270567 A CN 116270567A CN 202310242383 A CN202310242383 A CN 202310242383A CN 116270567 A CN116270567 A CN 116270567A
- Authority
- CN
- China
- Prior art keywords
- high sugar
- white
- swainsonine
- islet cells
- islet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 7
- 210000004153 islets of langerhan Anatomy 0.000 claims abstract description 36
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 claims abstract description 36
- 229960005566 swainsonine Drugs 0.000 claims abstract description 36
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000003914 insulin secretion Effects 0.000 claims abstract description 11
- 230000006907 apoptotic process Effects 0.000 claims abstract description 9
- 230000009467 reduction Effects 0.000 claims abstract description 9
- 230000005779 cell damage Effects 0.000 claims abstract description 3
- 208000037887 cell injury Diseases 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 12
- WHAXMKSMPRMSEQ-UHFFFAOYSA-N Aspidin AA Natural products COc1c(C)c(O)c(CC2=C(O)C(C)(C)C(=C(C(=O)C)C2=O)O)c(O)c1C(=O)C WHAXMKSMPRMSEQ-UHFFFAOYSA-N 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 6
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- -1 aspartyl Chemical group 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196133 Dryopteris Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical preparation for treating diabetes, and belongs to the technical field of diabetes treatment. The only active ingredient of the pharmaceutical preparation is the white swainsonine AA, and the invention discovers through cell experiments that the white swainsonine can effectively inhibit and protect islet cell injury caused by high sugar, reduce the reduction of insulin secretion capacity of islet cells caused by high sugar and inhibit islet cell apoptosis caused by high sugar. The invention widens the medicinal value and the economic value of the white swainsonine AA and simultaneously provides a new therapeutic drug for treating diabetes.
Description
Technical Field
The invention belongs to the technical field of diabetes treatment, and particularly relates to a pharmaceutical preparation for treating diabetes.
Background
Diabetes is a life-threatening and systemic endocrine-metabolic disease, and hyperglycemia and insufficient insulin secretion or action are typical features of diabetes. The number of diabetics is increasing year by year from the survey report of the international diabetes union. Diabetes patients often have diseases such as nephropathy and cardiovascular diseases, and the health and life quality of the patients are seriously affected, so that the diabetes treatment research has important significance.
Of the diabetics, type 2 diabetics account for over 90% of the population suffering from diabetes, and the main pathogenesis of type 2 diabetes is insulin resistance and islet B cell dysfunction. The existing research shows that compared with the normal population, the type 2 diabetes patients have obviously reduced number of islet B cells in the body, and the apoptosis rate of the islet B cells is also obviously increased. Hyperglycemia is the primary mechanism leading to islet cell depletion, and therefore, effective reduction of the damage to islet B cells caused by hyperglycemia to maintain islet B cell numbers is of great clinical importance.
Disclosure of Invention
The white aspidin AA is derived from rhizoma Dryopteris Crassirhizomatis, its English name is Albaspridin AA, and its molecular formula is C 21 H 24 O 8 The CAS number is 3570-40-9. Albastin AA has antibacterial activity and thus is formulated as an antibacterial agent, however, studies on white swainsonine AA are currently few, and its role in diabetes treatment is still blank.
Therefore, the invention aims to explore the application of the white swainsonine AA in the treatment of diabetes and widen the application range of the white swainsonine AA, and provide a novel therapeutic drug for the treatment of diabetes.
In order to achieve the above purpose, the present invention provides the following technical solutions:
the invention provides a medicinal preparation for treating diabetes, the core active ingredient of the medicinal preparation is white swainsonine AA, and the medicament also comprises a pharmaceutically acceptable carrier.
Preferably, the carrier comprises an excipient, carrier or diluent.
Preferably, the Bai Mianma AA inhibits the activity reduction of islet cells caused by high sugar, protects the damage of the high sugar to the islet cells, reduces the insulin secretion capacity reduction of the islet cells caused by the high sugar, and inhibits the apoptosis of the islet cells caused by the high sugar.
Secondly, the invention provides application of the white swainsonine AA as the only active ingredient in preparing the medicine for treating diabetes.
Preferably, the Bai Mianma AA inhibits the activity reduction of islet cells caused by high sugar, protects the damage of the high sugar to the islet cells, reduces the insulin secretion capacity reduction of the islet cells caused by the high sugar, and inhibits the apoptosis of the islet cells caused by the high sugar.
Preferably, the medicine takes the white swainsonine AA as the only effective component and is supplemented with a pharmaceutically acceptable carrier to prepare any pharmaceutically acceptable carrier.
Secondly, the invention provides application of the white swainsonine AA as the only active ingredient in preparing a medicament for inhibiting or protecting islet cell injury caused by high sugar.
Second, the present invention provides the use of aspidin AA as the sole active ingredient in the manufacture of a medicament for reducing the high sugar-induced decline in insulin secretion capacity of islet cells.
The invention has the beneficial effects that:
the invention discovers that the white swainsonine AA can be used as the only active ingredient to prepare the medicine for treating diabetes mellitus, widens the medicinal value and the economic value of the white swainsonine AA, and simultaneously provides a novel medicine for treating diabetes mellitus.
Drawings
FIG. 1 shows the effect of aspartyl AA on the high sugar induced islet cell apoptosis protein clear-Caspase 3.
Detailed Description
Example 1: effect of different concentrations of white aspidin AA on islet cell Activity
1) After the white swainsonine AA is completely dissolved by using DMSO, the white swainsonine AA is diluted into a 25,50,100,200,400 mu mol/L culture medium solution by using a DMEM culture medium;
2)2×10 4 inoculating INS-1 cells into 96-well plate, and culturing for 24After h, changing the culture medium into the culture medium solution of the white swainsonine AA with different concentrations, and adding a common DMEM culture medium into a control group;
3) After 24h incubation, MTT solution was added to 96-well plates and incubated at 37℃for 4h;
4) And adding dimethyl sulfoxide, shaking and uniformly mixing, and detecting an absorbance value at 570 nm.
TABLE 1 Effect of different concentrations of white aspidin AA on islet cell activity
| Group of | Concentration (mu mol/L) | Absorbance of light |
| Control group | 0.76±0.04 | |
| White swainsonine AA group | 25 | 0.76±0.04 |
| 50 | 0.75±0.04 | |
| 100 | 0.73±0.03 | |
| 200 | 0.73±0.03 | |
| 400 | 0.72±0.03 |
As can be seen from Table 1, the activity of the INS-1 cells was not significantly affected by the aspidin AA in the concentration range of 25-400. Mu. Mol/L.
Example 2: influence of Bessel AA on islet cell viability in high sugar environments
1)2×10 4 Inoculating INS-1 cells into a 96-well plate, culturing for 24 hours, removing the culture medium, adding a common DMEM culture medium into a control group, adding a culture medium containing glucose with a final concentration of 30mmol/L into a high sugar group, and respectively adding a culture medium containing 25, 100, 400 mu mol/L of white swainsonine AA+30mmol/L of glucose into a low-medium-high concentration group of white swainsonine AA;
2) After 24h incubation, MTT solution was added to 96-well plates and incubated at 37℃for 4h;
3) After adding dimethyl sulfoxide and shaking uniformly, the absorbance at 570nm was detected, and the results are shown in Table 2.
TABLE 2 Effect of white secalin AA on islet cell viability in high sugar environments
| Group of | Absorbance of light |
| Control group | 0.76±0.03 |
| High sugar group | 0.39±0.03** * |
| Low concentration white swainsonine AA group | 0.51±0.03 * |
| Medium concentration Bai Mianma element AA group | 0.63±0.02 ** |
| High concentration Bai Mianma element AA group | 0.64±0.03 ** |
Annotation: * P < 0.001, P < 0.05, P < 0.01.
According to Table 2, it can be seen that, the low, medium and high concentration of the white swainsonine AA can effectively inhibit the reduction of islet cell activity caused by high sugar, and as the result, when the concentration of the white swainsonine AA reaches 100 mu mol/L, the effect of inhibiting the reduction of islet cell caused by high sugar basically reaches the optimal effect, and the effect of continuously increasing the concentration is not obvious any more.
Example 3: protective effect of white swainsonine AA on islet cell viability in high-sugar environment
1)2×10 4 Inoculating the individual INS-1 cells into a 96-well plate, culturing for 18 hours, adding a common DMEM culture medium into a control group and a high sugar group, and adding a culture medium containing 100 mu mol/L of white swainsonine AA into a white swainsonine AA group;
2) After 6h of treatment, the medium was removed, the control group was added with normal DMEM medium, the high sugar group and the white swainsonine AA group were added with medium containing glucose at a final concentration of 30 mmol/L;
3) After 24h incubation, MTT solution was added to 96-well plates and incubated at 37℃for 4h;
4) After adding dimethyl sulfoxide and shaking uniformly, the absorbance at 570nm was detected, and the results are shown in Table 3.
TABLE 3 protective effect of white secomanin AA on islet cells in high sugar environments
| Group of | Absorbance of light |
| Control group | 0.77±0.04 |
| High sugar group | 0.38±0.04** |
| White swainsonine AA group | 0.52±0.03* |
Annotation: * P < 0.01, P < 0.05.
According to Table 3, it can be seen that the pretreatment of the white swainsonine AA can reduce the damage of high sugar to islet cells and plays a certain role in protection.
Example 4: effect of white aspartyl AA on high sugar-induced insulin secretion
1) Will be 1X 10 5 Inoculating INS-1 cells into a 24-well plate, culturing for 24 hours, removing the culture medium, adding a common DMEM culture medium into a control group, adding 30mmol/L glucose into a high-sugar group, and adding a culture medium containing 100 mu mol/L of white swainsonine AA+30mmol/L glucose into a white swainsonine AA group;
2) After 24h incubation, the medium was removed, 16.7mmol/L glucose KRBH buffer was added to each group, and after incubation at 37℃for 0.5h, the supernatants of each group were collected and assayed for insulin content using ELISA kit.
TABLE 4 Effect of white aspartyl AA on high sugar induced insulin secretion
| Group of | Insulin concentration (mu IU/L) |
| Control group | 6.59±0.23 |
| High sugar group | 4.13±0.29 |
| White swainsonine AA group | 5.42±0.32 |
From Table 4, we can conclude that the insulin secretion capacity of islet cells is reduced by the recovery of high sugar to some extent by the aspartyl AA.
Example 5: effect of Bessel AA on islet apoptosis due to high sugar
1) Will be 1X 10 5 Inoculating INS-1 cells into a 24-well plate, culturing for 24 hours, removing the culture medium, adding a common DMEM culture medium into a control group, adding 30mmol/L glucose into a high-sugar group, and adding a culture medium containing 100 mu mol/L of white swainsonine AA+30mmol/L glucose into a white swainsonine AA group;
2) Removing the culture medium after culturing for 24 hours, and adding protein lysate to extract a protein sample;
3) Preparing an electrophoresis gel, assembling an electrophoresis frame, loading different groups of protein samples, adjusting an electrophoresis apparatus to be at a constant voltage of 90V, and adjusting the voltage to be 120V after a protein Marker is completely separated until electrophoresis is finished;
4) After the electric rotating clamp is assembled and installed to the electric rotating groove, the power supply is adjusted to be constant current of 250mA, and the electric rotating is carried out for 1.5 hours;
5) Taking out the membrane, placing the membrane in a sealing solution, sealing for 1h, taking out the incubation primary antibody, and placing the membrane at 4 ℃ for incubation overnight;
6) After washing the membrane by using TBST, incubating the corresponding secondary antibody for 1h at room temperature;
7) After the film was washed, development exposure was performed, and the results obtained are shown in fig. 1.
From fig. 1, we can conclude that the white swainsonine AA can inhibit islet cell apoptosis caused by high sugar to some extent.
Claims (8)
1. A pharmaceutical preparation for treating diabetes, characterized in that the core active ingredient of the pharmaceutical preparation is white swainsonine AA, and the medicament also comprises a pharmaceutically acceptable carrier.
2. The pharmaceutical formulation of claim 1, wherein the carrier comprises an excipient, carrier or diluent.
3. The pharmaceutical formulation of claim 1, wherein the Bai Mianma AA inhibits the decrease in islet cell activity caused by high sugar, protects the damage of high sugar to islet cells, reduces the decrease in insulin secretion capacity of islet cells caused by high sugar, and inhibits apoptosis of islet cells caused by high sugar.
4. Application of white swainsonine AA as the sole active ingredient in preparing medicine for treating diabetes is provided.
5. The use according to claim 4, wherein the Bai Mianma AA inhibits the decrease in activity of islet cells caused by high sugar, protects the damage of high sugar to islet cells, reduces the decrease in insulin secretion capacity of islet cells caused by high sugar, and inhibits apoptosis of islet cells caused by high sugar.
6. The use according to claim 4, wherein the medicament is formulated with aspidin AA as the only active ingredient, supplemented with a pharmaceutically acceptable carrier.
7. The application of the white swainsonine AA as the only active ingredient in preparing the drugs for inhibiting or protecting the islet cell injury caused by high sugar.
8. The use of aspidin AA as the sole active ingredient in the manufacture of a medicament for reducing the reduction of insulin secretion capacity of islet cells caused by high sugar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310242383.2A CN116270567A (en) | 2023-03-10 | 2023-03-10 | Pharmaceutical preparation for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310242383.2A CN116270567A (en) | 2023-03-10 | 2023-03-10 | Pharmaceutical preparation for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116270567A true CN116270567A (en) | 2023-06-23 |
Family
ID=86797346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310242383.2A Pending CN116270567A (en) | 2023-03-10 | 2023-03-10 | Pharmaceutical preparation for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116270567A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080008819A (en) * | 2006-07-21 | 2008-01-24 | 한국생명공학연구원 | Fas inhibitory compounds from dryopteris crassirhiza and compositions for treatment and prevention of cancer and obesity containing the same as an active ingredient |
| CN106038900A (en) * | 2016-06-30 | 2016-10-26 | 济南星懿医药技术有限公司 | Medicine composition for treating diabetic nephropathy and preparation method thereof |
-
2023
- 2023-03-10 CN CN202310242383.2A patent/CN116270567A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080008819A (en) * | 2006-07-21 | 2008-01-24 | 한국생명공학연구원 | Fas inhibitory compounds from dryopteris crassirhiza and compositions for treatment and prevention of cancer and obesity containing the same as an active ingredient |
| CN106038900A (en) * | 2016-06-30 | 2016-10-26 | 济南星懿医药技术有限公司 | Medicine composition for treating diabetic nephropathy and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 吴寿金等: "绵马贯众化学成分的研究（I）", 《中草药》, vol. 27, no. 8, pages 458 - 459 * |
| 黄瑶等: "2种鳞毛蕨属植物醇提物的抗氧化、 降血糖及抗炎活性", 云南民族大学学报( 自然科学版), vol. 31, no. 2, pages 152 - 156 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sandler et al. | Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man | |
| CN111494466A (en) | A topical composition containing Cannabis sativa extract and its application | |
| CN111184714A (en) | Application of brucea javanica picrol in preparation of medicines for preventing or treating inflammatory diseases | |
| CN116270567A (en) | Pharmaceutical preparation for treating diabetes | |
| US20210106640A1 (en) | Method of chinese herbal medicine extract used for treating multiple diseases caused by drug resistant bacteria infection | |
| CN109180484B (en) | 2, 4-disubstituted phenol derivative compounds extracted from noni ferment, and extraction method and application thereof | |
| CN112006982A (en) | Stable levocetirizine hydrochloride oral solution and preparation method thereof | |
| CN111973593A (en) | Application of nitazoxanide and pharmaceutically acceptable salt thereof in preparation of medicines for treating bladder cancer | |
| LU101639B1 (en) | Application of Ilexgenin O in preparation of medicament for preventing and treating senile dementia | |
| CN108403980B (en) | Hypoglycemic plant extract effective part and preparation method and application thereof | |
| CN105687271B (en) | Application of phenolic acid compound in preparation of medicine for resisting diabetic foot drug-resistant bacteria infection | |
| CN108003099B (en) | Bisbenzyl tetrahydroisoquinoline compound and preparation method and application thereof | |
| CN111419852A (en) | Application of 3 α, 11 α -dihydroxy-lupin-20 (29) -alkene-28-acid in preparation of hypoglycemic drugs | |
| CN115304653B (en) | Four iridoid glycoside compounds extracted from dogwood, and preparation method and application thereof | |
| CN116327874B (en) | Pharmaceutical composition and external preparation for treating acne and preparation method thereof | |
| CN115105488B (en) | Application of Dankesterone A in preparation of medicines for treating hepatic fibrosis | |
| KR101208955B1 (en) | Pharmaceutical composition comprising piperazine dithioctate and glimepiride | |
| CN110585179B (en) | Application of Germacradienol and derivatives thereof in preparing medicine for treating neuroblastoma | |
| CN117180243B (en) | Use of carnosone in preparing medicine for preventing and/or treating Alzheimer disease | |
| CN115364076A (en) | Application of diterpenoid compound DB-022133 in preparation of medicine for treating gastric cancer | |
| CN117357543B (en) | Application of Sequiside L in breast cancer treatment | |
| CN113425709B (en) | Application of L-aspartic acid-beta-hydroxamic acid in preparation of medicine for treating type II diabetes | |
| CN115192571A (en) | Application of compound Rutaevin in preparation of medicine for treating gastric cancer | |
| RU2801300C2 (en) | Topical use of dioxidin for the treatment of otolaryngological diseases | |
| CN116270610A (en) | Application of carnosol in preparing myocardial protection medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |